Background: As the use of continuous glucose monitoring (CGM) increases, there is a need
to better understand key metrics of time in range 70-180 mg/dL (TIR70-180) and …

Background: There has been recent recognition of the limitations of hemoglobin A1C
(HbA1C) in describing both short-and long-term glycemic control. Continuous glucose …

Aims Although there is a linear relationship between time in range (TIR) and hemoglobin
A1c (HbA1c), a great variability of calculated TIR values for a given HbA1c, and vice versa …

Glycosylated hemoglobin (HbA1c) has been the sole surrogate marker for assessing
diabetic complications. However, consistently reported limitations of HbA1c are that it lacks …

Background: As the use of continuous glucose monitoring (CGM) has increased, time in
range (TIR) and other core CGM metrics are now emerging as the core metrics for clinical …

Objective: To bridge the gap between laboratory-measured hemoglobin A1c (HbA1c) and
continuous glucose monitoring (CGM)-derived time in target range (TIR), introducing TIR …

Aim To evaluate continuous glucose monitoring (CGM) metrics for use as alternatives to
glycated haemoglobin (HbA1c) to evaluate therapeutic efficacy. Methods We re‐analysed …

Aims To identify clinically useful associations between HbA1c levels and various continuous
glucose monitoring‐derived metrics. Methods We retrospectively analysed end‐of‐study …

Abstract Hemoglobin A1C (HbA1c) is used as an index of average blood glucose
measurement over a period of months and is a mainstay of blood glucose monitoring. This …

Abstract The International Consensus in Time in Range (TIR) was recently released and
defined the concept of the time spent in the target range between 70 and 180 mg/dL while …